Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
DPP4 Biologics Sequence Review Report 2026: Dipeptidyl peptidase 4 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DPP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DLL1 Biologics Sequence Review Report 2026: Delta-like protein 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DLL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DDR2 Biologics Sequence Review Report 2026: Discoidin domain-containing receptor 2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DDR1 Biologics Sequence Review Report 2026: Epithelial discoidin domain-containing receptor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL12 Biologics Sequence Review Report 2026: Stromal cell-derived factor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CXCL12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CX3CL1 Biologics Sequence Review Report 2026: Fractalkine Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CX3CL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN25 Biologics Sequence Review Report 2026: Claudin-25 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN25 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN24 Biologics Sequence Review Report 2026: Claudin-24 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN24 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN23 Biologics Sequence Review Report 2026: Claudin-23 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN23 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN22 Biologics Sequence Review Report 2026: Claudin-22 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN22 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN19 Biologics Sequence Review Report 2026: Claudin-19 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN19 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN17 Biologics Sequence Review Report 2026: Claudin-17 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
2
3
4
5
>>
1764
>